

## Drug Monograph

Drug/Drug **Afrezza® (insulin human) inhalation powder / Rapid**  
Class: **Acting Insulins**  
Prepared for: MO HealthNet  
Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Afrezza is now available as an inhalation powder containing 180 cartridges; 90 – 8 unit cartridges and 90 - 12 unit cartridges and 2 inhalers.

**Manufacturer:** Distributed by: MannKind Corporation™ Danbury, CT 06810

**Indications:** Afrezza is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Important limitations of use: in patients with type 1 diabetes, must use with a long-acting insulin; not recommended for the treatment of diabetic ketoacidosis; not recommended in patients who smoke.

**Costs:** \$1,623.45 per 180 cartridges of Afrezza Inhalation Powder. *Wholesale Acquisition Cost*

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Non-Preferred  
 Appropriate Indications  No PA Required

Prepared By: Jennifer Anderson PharmD  
Date: April 15, 2019